# Doximity, Inc. (DOCS)

Informational only - not investment advice.

CIK: 0001516513
SIC: 7371 Services-Computer Programming Services
SIC breadcrumb: [Services](/division/I/) > [Business Services](/major-group/73/) > [SIC 7371 Services-Computer Programming Services](/industry/7371/)
Latest 10-K filed: 2026-05-19
SEC page: https://www.sec.gov/edgar/browse/?CIK=1516513
Filing source: https://www.sec.gov/Archives/edgar/data/1516513/000151651326000025/docs-20260331.htm

## At a glance

FY2026 · period end 2026-03-31 · filed 2026-05-19 · accession 0001516513-26-000025 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001516513.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 644,863,000 USD | 2026 | verified |
| Net income | 196,051,000 USD | 2026 | verified |
| Assets | 1,123,687,000 USD | 2026 | verified |
| Free cash flow | 326,458,000 USD | 2026 | computed |
| Net margin | 30.40% | 2026 | computed |
| Operating margin | 33.33% | 2026 | computed |
| Revenue YoY | +13.05% | 2026 | computed |
| ROE | 20.62% | 2026 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2026 revenue ÷ FY2025 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | DOCS | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Revenue growth | 13.1% | 6.7% | 71 | 8 |
| FCF margin | 50.6% | 12.3% | 86 | 8 |
| ROA | 17.4% | 7.7% | 86 | 8 |
| Current ratio | 6.09 | 2.08 | 86 | 8 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 7371 Services-Computer Programming Services, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 644863000 | USD | 2026 | 2026-05-19 |
| Net income | 196051000 | USD | 2026 | 2026-05-19 |
| Assets | 1123687000 | USD | 2026 | 2026-05-19 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-05-19. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001516513.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  | 116,388,000 | 206,897,000 | 343,548,000 | 419,052,000 | 475,422,000 | 570,399,000 | 644,863,000 |
| Net income |  | 29,737,000 | 50,210,000 | 154,783,000 | 112,818,000 | 147,582,000 | 223,185,000 | 196,051,000 |
| Operating income |  | 22,163,000 | 53,303,000 | 113,536,000 | 125,108,000 | 163,878,000 | 227,800,000 | 214,920,000 |
| Gross profit |  | 101,488,000 | 175,701,000 | 303,761,000 | 365,562,000 | 424,753,000 | 514,525,000 | 574,537,000 |
| Diluted EPS |  | 0.13 | 0.23 | 0.70 | 0.53 | 0.72 | 1.11 | 0.98 |
| Operating cash flow |  | 26,199,000 | 82,973,000 | 126,575,000 | 179,602,000 | 184,096,000 | 273,265,000 | 326,458,000 |
| Capital expenditures |  | 285,000 | 245,000 | 1,912,000 | 1,701,000 | 147,000 | 0.00 | 0.00 |
| Share buybacks |  | 0.00 | 2,022,000 | 2,698,000 | 85,324,000 | 280,716,000 | 120,293,000 | 431,652,000 |
| Assets |  |  | 251,719,000 | 991,357,000 | 1,136,888,000 | 1,079,374,000 | 1,264,309,000 | 1,123,687,000 |
| Liabilities |  |  | 103,518,000 | 112,763,000 | 170,772,000 | 177,977,000 | 181,684,000 | 172,850,000 |
| Stockholders' equity | -32,935,000 | 1,136,000 | 66,743,000 | 878,594,000 | 966,116,000 | 901,397,000 | 1,082,625,000 | 950,837,000 |
| Cash and cash equivalents |  |  | 66,393,000 | 112,809,000 | 158,027,000 | 96,785,000 | 209,614,000 | 219,178,000 |
| Free cash flow |  | 25,914,000 | 82,728,000 | 124,663,000 | 177,901,000 | 183,949,000 | 273,265,000 | 326,458,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  | 25.55% | 24.27% | 45.05% | 26.92% | 31.04% | 39.13% | 30.40% |
| Operating margin |  | 19.04% | 25.76% | 33.05% | 29.86% | 34.47% | 39.94% | 33.33% |
| Return on equity |  |  | 75.23% | 17.62% | 11.68% | 16.37% | 20.62% | 20.62% |
| Return on assets |  |  | 19.95% | 15.61% | 9.92% | 13.67% | 17.65% | 17.45% |
| Liabilities / equity |  |  | 1.55 | 0.13 | 0.18 | 0.20 | 0.17 | 0.18 |
| Current ratio |  |  | 2.05 | 8.12 | 6.99 | 6.20 | 6.97 | 6.09 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001516513.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2023-Q2 | 2022-09-30 |  |  | 0.12 | reported discrete quarter |
| 2023-Q3 | 2022-12-31 |  |  | 0.16 | reported discrete quarter |
| 2024-Q1 | 2023-06-30 |  |  | 0.13 | reported discrete quarter |
| 2024-Q2 | 2023-09-30 | 113,612,000 | 30,602,000 | 0.15 | reported discrete quarter |
| 2024-Q3 | 2023-12-31 | 135,284,000 | 47,956,000 | 0.24 | reported discrete quarter |
| 2024-Q4 | 2024-03-31 | 118,057,000 | 40,618,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2024-06-30 | 126,676,000 | 41,377,000 | 0.21 | reported discrete quarter |
| 2025-Q2 | 2024-09-30 | 136,832,000 | 44,154,000 | 0.22 | reported discrete quarter |
| 2025-Q3 | 2024-12-31 | 168,603,000 | 75,196,000 | 0.37 | reported discrete quarter |
| 2025-Q4 | 2025-03-31 | 138,288,000 | 62,458,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2025-06-30 | 145,913,000 | 53,320,000 | 0.27 | reported discrete quarter |
| 2026-Q2 | 2025-09-30 | 168,525,000 | 62,059,000 | 0.31 | reported discrete quarter |
| 2026-Q3 | 2025-12-31 | 185,053,000 | 61,558,000 | 0.31 | reported discrete quarter |
| 2026-Q4 | 2026-03-31 | 145,372,000 | 19,114,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2027-Q1 | 2026-06-30 | 156,618,000 | 24,315,000 | 0.13 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from DOCS's latest 10-K: [/company/DOCS/business/](/company/DOCS/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from DOCS's latest 10-K: [/company/DOCS/risk-factors/](/company/DOCS/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1516513/000151651326000040/docs-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-08-06
Report date: 2026-06-30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and accompanying notes that are included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K, filed with the SEC on May 19, 2026. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, as described under the heading “Special Note Regarding Forward-Looking Statements” in this Quarterly Report on Form 10-Q. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled “Risk Factors” in Part 1, Item 1A of our Annual Report on Form 10-K or in other parts of this Quarterly Report on Form 10-Q. Our historical results are not necessarily indicative of the results that may be expected for any period in the future, and our interim results are not necessarily indicative of the results that may be expected for the full fiscal year or any other period. The last day of our fiscal year is March 31st. Our fiscal quarters end on June 30th, September 30th, December 31st, and March 31st. Fiscal 2027, our current fiscal year, will end on March 31, 2027.

Overview

We are the leading digital platform for U.S. medical professionals, with over 3 million registered members1 as of March 31, 2026. Our registered members represent more than 85% of U.S. physicians, spanning all 50 states and every medical specialty. As of March 31, 2026, the total number of U.S. physicians was approximately 1 million. We calculate U.S. physicians as all U.S. physicians (MDs/DOs) who are under the age of 76, not retired, hold an active medical license, and have a physician status on the National Provider Identifier (NPI) registry. To be included in our calculation of registered members as a percentage of U.S. physicians, we include those U.S. physicians who meet the above criteria and have registered on Doximity by claiming their pre-populated profile or creating a new profile.

Our mission is to help every physician be more productive and provide better care for their patients. We are physician-first, putting technology to work for doctors instead of the other way around. That guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians and their colleagues. We provide our members with AI-powered tools specifically built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Our Clinical AI Suite supports the full day-to-day workflow of a physician, from patient communication to documentation to answering clinical questions.

At the core of our platform is the largest medical professional network in the nation, which creates proximity within our community of doctors and other medical professionals. Verified members can search and connect with colleagues and specialists, which allows them to better coordinate patient care and streamline referrals. Our newsfeed addresses the ever increasing sub-specialization of medical expertise and volume of medical research by delivering news and information that is relevant to each physician’s clinical practice. We also support physicians in their day-to-day practice of medicine with mobile-friendly and easy-to-use workflow tools such as voice and video dialer, secure messaging, digital faxing, and our Clinical AI Suite, including Ask (formerly DoxGPT) and Scribe. Our business model is designed to both respect and support physicians while driving value for our customers through our Marketing, Hiring, and Workflow Solutions. Our revenue-generating customers, primarily pharmaceutical manufacturers and health systems, have access to a suite of commercial solutions that benefit from broad physician usage.

Our business model has delivered high revenue growth at scale with profitability. For the three months ended June 30, 2026 and 2025, we recognized revenue of $156.6 million and $145.9 million, respectively, representing a year-over-year growth rate of 7%. For the three months ended June 30, 2026 and 2025, our net income was $24.3 million and $53.3 million and our adjusted EBITDA was $74.8 million and $79.8 million, respectively. We have accomplished this while focusing on our core mission to help every physician be more productive and provide better care for their patients.

1 A registered member is a user who has completed the registration flow on Doximity by either claiming a pre-populated profile or creating a new profile.

24

Table of Contents

Key Business and Financial Metrics

We monitor a number of key business and financial metrics to assess the health and success of our business, including:

Customers with Trailing 12-Month Subscription Revenue Greater than $500,000. The number of customers with trailing 12-month (“TTM”) subscription revenue greater than $500,000 is a key indicator of the scale of our business and the value we create for large customers, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

The number of customers with at least $500,000 of TTM revenue has grown steadily in recent years as we have engaged new customers and expanded within existing ones. This cohort of customers accounted for approximately 83% of our revenue for the TTM ended June 30, 2026.

[[GREPCENT_TABLE]]
[["","June 30,"],["","2026","","2025"],["Number of customers with at least $500,000 of TTM revenue","127","","","119"]]
[[/GREPCENT_TABLE]]

Net Revenue Retention Rate. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Net revenue retention rate is calculated by taking the TTM subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.

[[GREPCENT_TABLE]]
[["","June 30,"],["","2026","","2025"],["Net revenue retention rate","107","%","","118","%"]]
[[/GREPCENT_TABLE]]

Quarterly Unique Active Providers using our Workflow Tools. Quarterly unique active providers2 using our Workflow Tools is a measure of our platform’s usage and adoption among healthcare providers on our platform. We calculate the number of unique active providers by counting providers who securely login and use any of the following workflow functions on our technology platform during the quarter: placing phone calls or video calls lasting more than 10 seconds, sending voicemails, or sending secure text messages using our Dialer communications tools; sending or receiving faxes; submitting a prompt on Ask (formerly DoxGPT), our HIPAA‑compliant generative AI clinical research tool and writing assistant; conducting research on prescription drugs; reviewing AI responses for our PeerCheck feature; scheduling via our on-call scheduling tool, Amion; or using our HIPAA-compliant ambient note taking tool, Scribe, for a patient visit. Each provider is counted once per quarter, even if they use multiple tools or use them many times.

Quarterly unique active providers using our workflow tools increased approximately 32% year-over-year compared to June 30, 2025, reflecting continued provider engagement and adoption of our clinical workflow tools across the physician network, including the growing impact of AI suite usage. This metric may fluctuate on a quarterly basis due to seasonal patterns in provider activity, including weather-related variability in Dialer usage, and greater potential variability from our more nascent AI tools including Ask and Scribe. Accordingly, we evaluate changes in this metric with consideration of these seasonal trends and believe year-over-year comparisons provide a more meaningful indicator of underlying provider engagement.

Non-GAAP Financial Measures

We use adjusted EBITDA and free cash flow to measure our performance, identify trends, formulate financial projections, and make strategic decisions.

Adjusted EBITDA

Adjusted EBITDA is a key measure we use to assess our financial performance and is also used for internal planning and forecasting purposes. We believe adjusted EBITDA is helpful to investors, analysts, and other interested parties because it can assist in providing a more consistent and comparable overview of our operations across our historical financial periods.

2 Providers are health care professionals with clinical / prescribing roles specifically Physicians (MD/DO), Nurse practitioners (NPs), Certified registered nurse anesthetists (CRNAs), Physician assistants (PAs), Pharmacists, and Medical students.

25

Table of Contents

We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

Adjusted EBITDA and adjusted EBITDA margin are non-GAAP measures and are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to the financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain expenses that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented in this Quarterly Report on Form 10-Q, limiting their usefulness as comparative measures.

The following table presents a reconciliation of net income to adjusted EBITDA, adjusted EBITDA margin, and net income margin (in thousands, except percentages):

[[GREPCENT_TABLE]]
[["","","","Three Months Ended June 30,"],["","","","","","2026","","2025"],["Net income","","","","","$","24,315","","","$","53,320"],["Adjusted to exclude the following:"],["Acquisition and other related expenses","","","","","\u2014","","","428"],["Stock-based compensation","","","","","36,752","","","21,865"],["Depreciation and amortization","","","","","4,287","","","2,794"],["Provision for income taxes","","","","","16,048","","","10,827"],["Change in fair value of contingent earn-out consideration liability","","","","","90","","","168"],["Other income, net","","","","","(6,719)","","","(9,630)"],["Adjusted EBITDA","","","","","$","74,773","","","$","79,772"],["Revenue","","","","","$","156,618","","","$","145,913"],["Net income margin","","","","","16","%","","37","%"],["Adjusted EBITDA margin","","","","","48","%","","55","%"]]
[[/GREPCENT_TABLE]]

Free Cash Flow

Free cash flow is a key performance measure that our management uses to assess our overall perf

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1516513/000151651326000025/docs-20260331.htm
Complete FY 2026 MD&A: /company/DOCS/mda/fy2026/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-05-19
Report date: 2026-03-31

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and accompanying notes that are included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, as described under the heading “Special Note Regarding Forward-Looking Statements” in this Annual Report on Form 10-K. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled “Risk Factors” or in other parts of this Annual Report on Form 10-K. Our historical results are not necessarily indicative of the results that may be expected for any period in the future.

A discussion regarding our financial condition and results of operations for the fiscal year ended March 31, 2026 compared to the fiscal year ended March 31, 2025 is presented below. A discussion regarding our financial condition and results of operations for the fiscal year ended March 31, 2025 compared to the fiscal year ended March 31, 2024 can be found in “Management's Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and filed with the SEC on May 20, 2025.

Overview

We are the leading digital platform for U.S. medical professionals, with over 3 million registered members2 as of March 31, 2026. Our registered members represent more than 85% of U.S. physicians, spanning all 50 states and every medical specialty, along with two-thirds of U.S. nurse practitioners and physician assistants, and approximately 90% of graduating U.S. medical students. As of March 31, 2026, the total number of U.S. physicians was approximately 1 million. We calculate U.S. physicians as all U.S. physicians (MDs/DOs) who are under the age of 76, not retired, hold an active medical license, and have a physician status on the National Provider Identifier (NPI) registry. To be included in our calculation of registered members as a percentage of U.S. physicians, we include those U.S. physicians who meet the above criteria and have registered on Doximity by claiming their pre-populated profile or creating a new profile.

Our mission is to help every physician be more productive and provide better care for their patients. We are physician-first, putting technology to work for doctors instead of the other way around. That guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians and their colleagues. We provide our members with AI-powered tools specifically built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Our Clinical AI Suite supports the full day-to-day workflow of a physician, from patient communication to documentation to answering clinical questions.

At the core of our platform is the largest medical professional network in the nation, which creates proximity within our community of doctors and other medical professionals. Verified members can search and connect with colleagues and specialists, which allows them to better coordinate patient care and streamline referrals. Our newsfeed addresses the ever increasing sub-specialization of medical expertise and volume of medical research by delivering news and information that is relevant to each physician's clinical practice. We also support physicians in their day-to-day practice of medicine with mobile-friendly and easy-to-use workflow tools such as voice and video dialer, secure messaging, digital faxing, and our Clinical AI Suite, including Ask (formerly DoxGPT) and Scribe. Our business model is designed to both respect and support physicians while driving value for our customers through our Marketing, Hiring, and Workflow Solutions. Our revenue-generating customers, primarily pharmaceutical manufacturers and health systems, have access to a suite of commercial solutions that benefit from broad physician usage.

Our business model has delivered high revenue growth at scale with profitability. For the fiscal years ended March 31, 2026, 2025 and 2024, we recognized revenue of $644.9 million, $570.4 million, and $475.4 million, respectively, representing year-over-year growth rates of 13% and 20%, respectively. Our net income was $196.1 million, $223.2 million, and $147.6 million for the fiscal years ended March 31, 2026, 2025, and 2024, respectively. For the fiscal years ended March 31, 2026, 2025 and 2024, we generated adjusted EBITDA of $357.8 million, $313.8 million, and $230.5 million, respectively. We have accomplished this while focusing on our core mission to help every physician be more productive and provide better care for their patients.

2 A registered member is a user who has completed the registration flow on Doximity by either claiming a pre-populated profile or creating a new profile.

49

Table of Contents

Impact of Macroeconomic Events

Unfavorable conditions in the economy may negatively affect the growth of our business and our results of operations. For example, macroeconomic events and policy uncertainty may slow decision making and budget allocation and reduce discretionary marketing spend at pharmaceutical companies. Adverse changes in budget allocation and discretionary marketing spend could impact our business, collection of accounts receivable and our expected cash flow generation, which may adversely impact our financial condition and results of operations.

We continue to closely monitor the impact of policy and macroeconomic uncertainties on all aspects of our business. While these uncertainties have not had a material adverse impact on our financial condition and results of operations to date, the extent to which these events and future policy and macroeconomic events will impact our business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted.

Key Business and Financial Metrics

We monitor a number of key business and financial metrics to assess the health and success of our business, including:

Customers with Trailing 12-Month Subscription Revenue Greater than $500,000. The number of customers with trailing 12-month, or TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

The number of customers with at least $500,000 of revenue has grown steadily in recent years as we have engaged new customers and expanded within existing ones. This cohort of customers accounted for approximately 83% of our revenue in fiscal 2026.

[[GREPCENT_TABLE]]
[["","March 31,"],["","2026","","2025","","2024"],["Number of customers with at least $500,000 of revenue","125","","118","","100"]]
[[/GREPCENT_TABLE]]

Net Revenue Retention Rate. Net revenue retention rate is calculated by taking the TTM subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.

[[GREPCENT_TABLE]]
[["","March 31,"],["","2026","","2025","","2024"],["Net revenue retention rate","109","%","","119","%","","114","%"]]
[[/GREPCENT_TABLE]]

Quarterly Unique Active Providers using our Workflow Tools. Quarterly unique active providers3 using our Workflow Tools is a key performance indicator of our platform’s adoption and long-term growth potential among providers on our platform. We calculate the number of unique active providers by counting providers who securely login and use any of the following workflow functions on our technology platform during the quarter: placing phone calls or video calls lasting more than 10 seconds, sending voicemails, or sending secure text messages using our Dialer communications tools; sending or receiving faxes; submitting a prompt on Ask (formerly DoxGPT), our HIPAA‑compliant generative AI clinical research tool and writing assistant; conducting research on prescription drugs; reviewing AI responses for our PeerCheck feature; scheduling via our on-

3 Providers are health care professionals with clinical / prescribing roles specifically Physicians (MD/DO), Nurse practitioners (NPs), Certified registered nurse anesthetist (CRNAs), Physician assistants (PAs), Pharmacists, and Medical students

50

Table of Contents

call scheduling tool, Amion; or using our HIPAA-compliant ambient note taking tool, Scribe, for a patient visit. Each provider is counted once per quarter, even if they use multiple tools or use them many times.

The figures in the following table are presented in millions:

[[GREPCENT_TABLE]]
[["","March 31,"],["","2026","","2025","","2024"],["Quarterly unique active providers using our workflow tools","0.81","","","0.62","","","0.58"]]
[[/GREPCENT_TABLE]]

Components of Results of Operations

Revenue

Marketing Solutions. Our customers purchase a subscription to Marketing Solutions, either directly or through marketing agencies, for the ability to share tailored content on the Doximity platform via a variety of modules for defined time periods. We generally bill customers either upon contract execution for a portion of the contract, with the remainder billed based on various time-based milestones, or on a monthly basis beginning in the month services are launched. When revenue is recognized in advance of billings, we record unbilled revenue. Unbilled revenue is recorded on the consolidated balance sheets within prepaid expenses and other current assets. Subscriptions to Marketing Solutions include the following contractual arrangements:

•Integrated and other subscriptions that are not tied to a single module per month but allow customers to utilize a given module or combination of modules during the subscription period, subject to limits on the total number of modules launched in a given period of time, active at any given time, and members targeted.

•Subscriptions for specific modules delivered on a monthly basis to a consistent number of targeted Doximity members during the subscription period.

For these subscription-based contractual arrangements, pricing is based on the number and composition of the targeted Doximity members, and on the specific modules purchased. We recognize revenue over time as control of the service is transferred to the customer.

Hiring and Workflow Solutions. We provide Hiring Solutions customers access to our platform which enables them to post job openings or deliver a fixed number of monthly messages to our network of medical professionals. We offer Workflow Solutions customers access to telehealth tools, on-call scheduling, and our Clinical AI Suite, including Dialer, Scribe and Ask, during the subscription period. Hiring and Workflow Solutions contracts are noncancelable and customers are billed in ann

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2026 MD&A: /company/DOCS/mda/fy2026/
All MD&A years: /company/DOCS/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2025 MD&A](/company/DOCS/mda/fy2025/): filed 2025-05-20; accession 0001516513-25-000056 (https://www.sec.gov/Archives/edgar/data/1516513/000151651325000056/docs-20250331.htm)
- [FY 2024 MD&A](/company/DOCS/mda/fy2024/): filed 2024-05-23; accession 0001516513-24-000035 (https://www.sec.gov/Archives/edgar/data/1516513/000151651324000035/docs-20240331.htm)
- [FY 2023 MD&A](/company/DOCS/mda/fy2023/): filed 2023-05-26; accession 0001516513-23-000036 (https://www.sec.gov/Archives/edgar/data/1516513/000151651323000036/docs-20230331.htm)
- [FY 2022 MD&A](/company/DOCS/mda/fy2022/): filed 2022-05-27; accession 0001516513-22-000037 (https://www.sec.gov/Archives/edgar/data/1516513/000151651322000037/docs-20220331.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 7371 Services-Computer Programming Services) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity

Macro-to-micro threads including this sector: [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/DOCS.md · JSON record: /company/DOCS.json · verified financials: /company/DOCS/financials.json / /company/DOCS/financials.csv · machine TOC for the whole site: /llms.txt